A subset of patients with neurocysticercosis developed chronic or recurrent perilesional inflammation and required long-term and high-dose corticosteroid therapy. Such therapy frequently results in severe adverse effects. The purpose of this study was to determine whether methotrexate can be used as an effective corticosteroid-sparing or replacement agent in patients with complicated neurocysticercosis.
Neurocysticercosis is caused by infection of the CNS with the larval form of the human tapeworm, Taenia solium. Clinical manifestations include seizures, headaches, and focal neurological deficits and are most often a result of cerebral inflammation that occurs in the context of degenerating or dead cysts [1] . Because of this, patients with neurocysticercosis are frequently administered corticosteroids to decrease the inflammation that normally occurs during the course of the disease or to decrease the anticipated perilesional inflammation that accompanies anthelmintic treatment [1] . Although there is significant morbidity associated with parenchymal neurocysticercosis, it can generally be effectively treated and usually requires only a short course of cor-ticosteroids, if any, to attenuate symptoms that arise from perilesional inflammation around degenerating cysts [1] [2] [3] .
Some patients, however, develop long-standing chronic or recurrent perilesional inflammation that can trigger recurrent seizures or focal neurological symptoms. This problem is most serious in patients with subarachnoid lesions in whom the parasite is often difficult to eliminate [4] . A significant cause of morbidity in areas of endemicity, relentless chronic inflammation associated with subarachnoid neurocysticercosis frequently occurs in untreated as well as treated patients and can result in lacunar infarcts, focal neurological deficits, and hydrocephalus [5] . Neurological complications also occur in a subset of patients with dead parasites who develop recurrent edema around parenchymal calcifications, possibly in response to sporadic release of retained parasite antigens [6] .
Although not yet histologically proven, edema around calcifications likely represents inflammation and is associated with increased frequency of seizures [6] [7] [8] [9] .
Consequently, the most serious types of neurocysticercosis often require long-term and high-dose corticosteroid therapy. Such treatment can lead to severe and even life-threatening adverse effects [10] . Despite these risks, to our knowledge, there have been no clinical or experimental studies evaluating the efficacy of any corticosteroid-sparing drug therapy for patients with neurocysticercosis.
Recently, the use of high-dose and/or long-term corticosteroid treatment of complicated neurocysticercosis resulted in severe toxicities in several patients in our clinic that required consideration of alternative immunosuppressive medications. We opted to use methotrexate, because it is generally well tolerated at dosages р25 mg/week and is well established as an efficacious corticosteroid-sparing or replacement therapy for a broad range of inflammatory disorders [11] [12] [13] [14] .
Previously, we reported the successful use of methotrexate as a corticosteroid-sparing agent in 1 patient with neurocysticercosis who experienced recurrent perilesional edema following treatment of large parenchymal cysts [15] . In this report, we describe 4 other patients with neurocysticercosis who have been administered methotrexate. Our results suggest that methotrexate is an effective and safe steroid-sparing or replacement medication for the treatment of complicated neurocysticercosis.
METHODS
Patients who required prednisone (15 mg/day) or its equivalent for у2 months, were likely to require long-term corticosteroid therapy by nature of their disease, developed serious complications due to corticosteroids, or presented with a long-term history of corticosteroid use and had continued evidence of ongoing inflammation were eligible for methotrexate treatment. Patients were observed frequently at the Clinical Center of the National Institutes of Health (Bethesda, MD) and by their own local physicians, when possible. Complete blood cell counts and liver enzyme panels were performed weekly for the first month, every other week for the next 2 months, and then every other month. Patients were monitored clinically for CNS signs and symptoms and underwent frequent MRIs to determine the degree and extent of perilesional enhancement and/or edema. All patients underwent regular neurological examinations, and those with visual symptoms had serial eye examinations by an opthalmologist. Approved informed consent was obtained, and clinical research was conducted in accordance with guidelines for human experimentation, as specified by the Helsinki Declaration of 1975, and revised in 1983, by the US Department of Health and Human Services (Washington, DC). This study was approved by the National Institute of Allergy and Infectious Diseases Institutional Review Board.
Four of 7 patients who received methotrexate are described below. Of the remainder, 1 patient was described previously [15] , a second patient sought medical care elsewhere shortly after initiating therapy, and a third patient has only recently commenced methotrexate therapy and is still being evaluated. One day after finishing the course of albendazole, the patient experienced 2 episodes of confusion and incoherent speech. Additional MRI revealed a decrease in the size of the subarachnoid cysts and less enhancement in the subarachnoid spaces but new lacunar infarcts in the left globus pallidus and hypothalamus. The dosage of prednisone was increased to 60 mg/day and then tapered off by 19 October 2002. The following day, he developed a facial droop and collapsed as a result of weakness of the right lower extremity. MRI revealed new lacunar infarcts in the right putamen, right caudate, and left internal capsule. Prednisone therapy was restarted at 60 mg/ day. On 28 October 2002, patient 1 developed vomiting and was prescribed dexamethasone (16 mg/day), in place of prednisone, and a 3-month course of albendazole.
REPORTS
Although patient 1's symptoms improved, he developed severe complications associated with the use of corticosteroids, including Cushing syndrome, diabetes mellitus requiring insulin, depression, glaucoma, and proximal muscle weakness. Methotrexate treatment (7.5 mg/week) commenced on 23 January 2003, and the dose of corticosteroids was tapered very gradually over the next 6 months. Once corticosteroid therapy was finished, diabetes resolved, and the patient was able to discontinue insulin therapy. The MRI findings remained stable, with no further leptomeningeal enhancement, although mild communicating hydrocephalus persisted. The dosage of methotrexate was increased to 10 mg/week in February 2004 because lumbar puncture revealed mild CSF pleocytosis (28 WBCs/mL), as well as a persistently elevated protein level (95 mg/dL). During the same month, the patient developed bilateral aseptic necrosis of his hips, a likely complication of prolonged corticosteroid use, and required bilateral hip replacements. Patient 1 has been asymptomatic, with normal neurologic status, during the past 3 years of methotrexate therapy. figure  3 ; months 0-17) [9] . During the subsequent 3 months, she was successfully tapered off corticosteroid therapy and then experienced no symptoms for 13 months. 
DISCUSSION
In this report, we described the beneficial use of methotrexate as a corticosteroid-sparing agent in 4 cases of severe neurocysticercosis with chronic or recurrent cerebral inflammation. Patients 1 and 2 had subarachnoid neurocysticercosis and required long-term immunosuppression to prevent lacunar infarcts and visual impairment, respectively. Both patients developed significant adverse effects from corticosteroid treatment. The addition of methotrexate allowed for successful tapering of corticosteroid therapy in both patients. The use of methotrexate by patient 3 enabled stabilization and the partial reversal of hydrocephalus caused by chronic cysticercosisdriven inflammation, preventing the need for a ventriculoperitoneal shunt. Patient 4 has a long history of seizures in association with recurrent perilesional edema around calcified cysts. Since initiation of methotrexate therapy, her episodes of perilesional edema have ceased, and the frequency of seizures has markedly decreased in the absence of corticosteroid therapy. For all 4 patients, significant corticosteroid-sparing effects were obtained using р20mg of methotrexate per week.
In this study, all of the patients were given folic acid supplementation, because it has been shown to decrease the risks of chronic methotrexate therapy without significantly diminishing its beneficial anti-inflammatory effects [16, 17] . Although none of the patients in this report developed known methotrexaterelated adverse effects, it is important to note that patient 2 developed probable regrowth of a portion of a subarachnoid cyst during methotrexate therapy. Although incomplete parasite eradication in response to anthelmintic therapy is well documented in subarachnoid neurocysticercosis [4] , we cannot exclude the possibility that chronic methotrexate therapy in patient 2 prevented the patient's immune system from completely killing the parasite. On the other hand, we also cannot exclude the possibility that methotrexate may have some cysticidal effect.
In conclusion, this report demonstrates that methotrexate can be a beneficial agent for the treatment of patients with neurocysticercosis with persistent or recurrent inflammation. At this time, we do not recommend methotrexate as first-line therapy to control inflammation in neurocysticercosis. The onset of action during methotrexate therapy is slow, and our experience is very limited. Furthermore, the majority of patients with neurocysticercosis only require a short course, if any, of corticosteroids to control inflammation induced by dying parasites. For patients with neurocysticercosis who develop chronic or recurrent cerebral inflammation, however, our experience suggests that methotrexate can be very beneficial as a corticosteroid-sparing or replacement agent.
